Regeneron Expands CytomX Cancer Partnership for Bispecific Therapies

Regeneron Pharmaceuticals (NASDAQ: REGN) announced an expansion of its partnership with CytomX Therapeutics to develop conditionally activated bispecific cancer therapies. These therapies aim to more precisely target cancer cells while reducing side effects.

Expanded Partnership Details

The new partnership involves developing several therapeutic candidates using CytomX's Probody™ technology, which allows the drug to be activated only in the tumor microenvironment. Under the agreement, Regeneron will pay CytomX upfront and development payments, with potential milestone payments reaching approximately $4 billion.

The Product

Conditionally activated bispecific therapeutics are antibodies that bind to two different targets simultaneously but remain inactive until they reach the tumor microenvironment. This reduces systemic toxicity and increases treatment efficacy.

Pricing and Availability

Neither company has disclosed pricing details or a timeline for clinical trials. The development process is expected to take several years before regulatory approvals.

Competition

Regeneron faces competition from companies like Merck (MRK) and Bristol-Myers Squibb (BMY) in the cancer immunotherapy space. However, the Probody™ technology may provide a competitive edge.

Potential Impact on the Company

If successful, these therapies could bolster Regeneron's oncology pipeline and provide new revenue streams. However, success depends on clinical trial results and regulatory approvals.